Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Linda Burghardt, PhD, a researcher in Great Neck, New York, started taking semaglutide because her doctor thought it might ...

CMS has launched the BALANCE Model, a five-year test to lower costs & expand Medicare access to GLP-1 weight-loss drugs while ...

When I first started following news about GLP‑1 drugs, everything revolved around injections that patients had to store, ...

As Indiana enters 2026, a major shift in the healthcare landscape is promising to make high-demand weight-loss medications more accessible to millions. With ...

Novo Nordisk faces GLP-1 headwinds after the FDA-approved Wegovy pill, and LLY gains share, margins erode, and the pipeline ...

Danish drugmaker Novo Nordisk is launching its once-daily Wegovy pill in the United States on Monday, offering doses of 1.5 ...

Novo’s oral Wegovy launch has intensified competition for Eli Lilly heading into 2026. ・Lilly’s outlook hinges on oral drug ...

Danish pharmaceutical giant Novo Nordisk has officially launched its once-daily Wegovy weight-loss pill in the United States, ...

Starting next week, Danish company Novo Nordisk is launching its Wegovy weight loss pill in the US. Consumers can purchase ...